English  |  正體中文  |  简体中文  |  0  
???header.visitor??? :  51782449    ???header.onlineuser??? :  1101
???header.sponsordeclaration???
 		 
???search.scope??? ???search.advance???
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???
???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
Repositories
Author
Title
Date
???ui.leftmenu.statisticschart???
???ui.leftmenu.realtimefacts???
???ui.leftmenu.trend???

???index.news???
2019臺灣學術機構典藏
研討會
機構典藏系統RC7版本已
發佈

???ui.leftmenu.copyrighttitle???
???ui.leftmenu.copyrightpublisher???
???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
機構典藏計畫網站
ROAR
OpenDOAR
SHERPA
OAIster
JAIRO
Ira
DSPACE
RWWR
臺大學術典藏NTU Scholars
???tair.name??? >  ???browser.page.title.author???

"lu s"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 46-55 of 95  (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-05-26T09:26:42Z Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) Tamura T.;Morita S;Lim W.T;Cheng Y;Ichinose Y;Maemondo M;Chang J;Goto K;Takahashi T;Nishio M;Sugawara S;Chih-Hsin Yang;Soo R.A;Zhang L;Shi Y.K;Yamamoto N;Nakagawa K;Mok T.S.K;Lu S;Nokihara H; Nokihara H; Lu S; Mok T.S.K; Nakagawa K; Yamamoto N; Shi Y.K; Zhang L; Soo R.A; CHIH-HSIN YANG; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim W.T; Morita S; Tamura T.
臺大學術典藏 2020-05-26T09:26:42Z A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer Lee J.C; Kim G.W; Allen J.C; Siddiqui F.J; Soh S.X; Lim W.-T.;Ong S.T;Tan E.-H;Tan D.S;Tan T.J;Ahn M.-J;Lee J.Y;Lee S.-H;Lee J.-K;Zhou C;Zhao M;Chih-Hsin Yang;Lee J.-H;Isobe K;Lu S;Niu X;Matsuo K;Yano S;Ebi H;Chin T.-M;Soo R.A;Mano H;Soda M;Yatabe Y;Lee J.C;Kim G.W;Allen J.C;Siddiqui F.J;Soh S.X; Yatabe Y; Soda M; Mano H; Soo R.A; Chin T.-M; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee J.-H; CHIH-HSIN YANG; Zhao M; Zhou C; Lee J.-K; Lee S.-H; Lee J.Y; Ahn M.-J; Tan T.J; Tan D.S; Tan E.-H; Ong S.T; Lim W.-T.
臺大學術典藏 2020-05-26T09:26:42Z Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:40Z EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6 Chih-Hsin Yang;Kim M;Massey D;Gibson N;Hirsh V;O'Byrne K;Yamamoto N;Mok T;Schuler M;Hou M;Li W;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:34Z Phase II study of crizotinib in east asian patients with ROS1-positive advanced non?�small-cell lung cancer Goto K.;Wilner K.D;Usari T;Paolini J;Roychowdhury D;Kemner A;Yamanaka T;Takahashi T;Ahn M.-J;Yamamoto N;Yang J.-J;Seto T;Zhou J;Lu S;Kim D.-W;Chih-Hsin Yang;Wu Y.-L; Wu Y.-L; CHIH-HSIN YANG; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K.
臺大學術典藏 2020-05-26T09:26:32Z Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) O?�Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG; Schuler M; Mok T; Yamamoto N; Huang Y; Lu S; Hu C.-P; Feng J; Sequist L.V; Hirsh V; Wu Y.-L; Chih-Hsin Yang;Lungershausen J;M?rten A;Massey D;Zhou C;Geater S.L;O??Byrne K;Yamamoto N;Mok T;Schuler M;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Hirsh V;Wu Y.-L
臺大學術典藏 2020-05-26T09:26:22Z Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos Chang J.W.C; Alip A; Peters S; Douillard J.-Y.; Soo R.A; Park K; Mitsudomi T; Azrif M; CHIH-HSIN YANG; Tan D.S.W; Kim D.-W; Wu Y.-L;Planchard D;Lu S;Sun H;Yamamoto N;Kim D.-W;Tan D.S.W;Chih-Hsin Yang;Azrif M;Mitsudomi T;Park K;Soo R.A;Chang J.W.C;Alip A;Peters S;Douillard J.-Y.; Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N
臺大學術典藏 2020-05-26T09:26:21Z Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N.
臺大學術典藏 2020-05-26T09:26:20Z First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K.
臺大學術典藏 2020-05-26T09:26:20Z First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials Schuler M;Paz-Ares L;Sequist L.V;Hirsh V;Lee K.H;Wu Y.-L;Lu S;Zhou C;Feng J;Ellis S.H;Samuelsen C.H;Tang W;M?rten A;Ehrnrooth E;Park K;Chih-Hsin Yang; Schuler M; Paz-Ares L; Sequist L.V; Hirsh V; Lee K.H; Wu Y.-L; Lu S; Zhou C; Feng J; Ellis S.H; Samuelsen C.H; Tang W; Märten A; Ehrnrooth E; Park K; CHIH-HSIN YANG

Showing items 46-55 of 95  (10 Page(s) Totally)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page

DSpace Software Copyright © 2002-2004  MIT   &  Hewlett-Packard   /   Enhanced by   NTU Library IR team